xCELLigence RTCA eSight - 成像和阻抗
使用 RTCA eSight 软件可轻松进行在线数据采集和离线数据分析,符合 FDA 21 CFR Part 11 法规要求。
- RTCA Analyzers
Request a Quote
Product Details
- 将基于阻抗的无标记 xCELLigence 实时细胞分析技术与具有红绿蓝(5x、10x 和 20x 物镜)三色荧光的活细胞成像技术相结合,增强对细胞分析及其结论的信心
- 全孔成像扩展:在进行 QC 或定量和监测细胞生长时可观察整个孔的情况
- 信息丰富的多重检测在同一个孔中结合细胞阻抗和成像,所有操作都可以在培养箱内完成
- 无论是 2D 还是 3D 细胞培养,都可以通过简单的工作流程提供生理相关的数据,该工作流程能够适应不同的实验方案,可同时监测细胞活力、细胞行为、细胞功能
- 灵活的活细胞成像,支持明场、三个荧光通道、多种孔板形式(6、12、24、48、96 或 384 孔)和容器类型(35 或 60 mm 培养皿),以及用户自定义实验流程
- 分析细胞数量、增殖、细胞大小/形状、形态变化和细胞-基底粘附强度的连续读数结果
- 成像通量提升,可同时支持 5 块 96 孔常规微孔板(所有 5 个板位),支持 3D 类器官分析,并内置 21 CFR Part 11 合规功能,确保实现安全、可审计的数据管理。
- Key Literature
-
Download Literature
Download a product brochure or data sheet
- Brochures
- English
- 23 Nov 2021
- 72.95 KB
AI-Powered, Label-Free Cell Segmentation, Counting, and Fluorescence-Based Classification
AI-powered, label-free cell segmentation in RTCA eSight enables robust brightfield cell counting and fluorescence-assisted classification across diverse assays,improving throughput and reproducibility.
- Application Notes
- English
- 30 Jun 2026
- 7.95 MB
- Application Notes
- Article Reprints
- Flyers
- Posters
- Specifications
- Technical Overviews
Videos
In Vivo DNA-launched Bispecific T Cell Engager Targeting IL-13Ra2 Controls Tumor Growth in an Animal Model of Glioblastoma Multiforme
Immuno-oncology research is changing the landscape of cancer treatment by harnessing the immune system to attack cancer cells. These immunotherapies utilize both the adaptive and innate arms of the immune system, playing a pivotal role in a host’s defense against tumors. Join the Agilent Immuno-Oncology webinar series and learn how experts in the field are making groundbreaking discoveries and taking steps towards a cancer-free world. Glioblastoma is an aggressive tumor with poor survival rates. Bispecific T cell engagers (BTEs) against different cancers are in various stages of clinical development. Toxicity resulting from cytokine release syndrome and the short half-life of BTEs, which necessitates continuous infusion—complicating delivery and increasing costs—are major challenges in the field. Here we describe the development of in vivo DNA-launched BTEs (dBTEs) with highly focused targeting of interleukin-13 receptor a2 (IL-13Ra2), a glioblastoma cell-surface target. We developed 4 BTEs targeting 2 epitopes of IL-13Ra2 and studied how heavy-light chain orientation affects BTE function. The dBTEs induced T cell activation, cytokine production, and tumor cytolysis in the presence of IL-13Ra2+ tumor cells, but we observed unique patterns of immune activation. We found a strong correlation between granzyme B secretion and dBTE-induced cytolysis of specific and nonspecific tumors. We down-selected dBTE PB01-forward based on lower cytokine induction profile and highest activation specificity. In vivo, dBTE PB01-forward demonstrated an improved half-life versus intravenous recombinant BTE delivery. In an orthotopic glioblastoma model, dBTE PB01-forward controlled tumor growth, improving animal survival, supporting the hypothesis that the blood-brain barrier does not affect the function of systemically delivered dBTE. Further study of PB01-forward for targeting glioblastoma and other IL-13Ra2+ cancers is warranted.
Armor CAR T Cells with Enhanced Potency for Cancer Immunotherapy
Explore rapid generation of non-activated CAR T cells with enhanced potency for cancer immunotherapy in this on-demand webinar from Agilent.
In process assessment of critical process parameters impacting CAR T cell potency, metabolic fitness and phenotype
Explore how Agilent's cell analysis tools enhance CAR-T cell manufacturing by providing real-time insights into immune phenotype and metabolic fitness.
Dr. Zelia Geouveia
Institut Curie
We are a laboratory working in cancer research, namely chimeric antigen receptor (CAR)-T cells targeting different antigens in the tumor. We were seeking a high throughput platform that would allow us to evaluate CAR-T cells killing in real-time. We were also interested in visualizing the killing in real time. The xCELLigence RTCA eSight was one of the technologies that could provide such information using impedance and live cell imaging (one machine, two different and precious information). When compared with other instruments that could provide imaging information only, the image quality was similar but we would not have the impedance for comparison. Thus, we decided that having both
View MoreCarole Perrot 博士
核心实验室主任, 约翰·霍普金斯儿童医院 (Tampa, FL)
“xCELLigence RTCA eSight 的 AI 分析模块大大减少了用户在图像分析上耗费的时间。它能针对各种细胞类型和实验条件实现自动化分析且性能稳定,在提高工作流程效率的同时还有助于确保获得可重现的结果。作为支撑多项科研课题的共享平台,xCELLigence 无疑是我们最核心的仪器之一,它简化了复杂的分析工作,让广大科研人员得以轻松开展先进的成像分析。”
View MoreAgilent xCELLigence RTCA 仪器助力 FDA 新批准疗法的效价测定程序开发
Agilent xCELLigence 实时细胞分析 (RTCA) 技术为 Autolus Therapeutics 公司最近获批的 CAR-T 疗法 AUCATZYL 提供了精准可靠的测试支持,有力推动了效价测定程序的开发与应用。安捷伦通过提供准确可靠的细胞分析技术,帮助 Autolus 建立了强大的分析方法。
- 15 Jul 2025
- FAQs
-
- Instruction Sheets
- Site Preparation Checklists
- User Manuals